Takeda Pharmaceutical (TAK) Asset Writedowns and Impairment (2018 - 2026)

Takeda Pharmaceutical has reported Asset Writedowns and Impairment for 9 years, with the latest figure at $188.2 million in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 1055.34% year-over-year to $188.2 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 108.55% increase from a year earlier, with the FY2026 full-year figure at $929.2 million, up 32.86% from the prior year.
• Asset Writedowns and Impairment was $188.2 million for Q2 2026 at Takeda Pharmaceutical, down from $324.7 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $823.1 million in Q3 2023, with the low at $14.2 million in Q4 2024.
• Average Asset Writedowns and Impairment over 5 years is $206.2 million, with a median of $133.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Asset Writedowns and Impairment surged 22639.3% in 2022, then sank 91.8% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at $42.6 million in 2022, then advanced by 20.33% to $51.3 million in 2023, then slumped by 72.26% to $14.2 million in 2024, then jumped by 249.41% to $49.7 million in 2025, then jumped by 278.75% to $188.2 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $188.2 million (Q2 2026), $324.7 million (Q1 2026), and $49.7 million (Q4 2025), per Business Quant data.